Nasal spray test could make allergy shots smarter and cheaper

NCT ID NCT04544774

Recruiting now Knowledge-focused Sponsor: Universitaire Ziekenhuizen KU Leuven Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a nasal allergen provocation test (NAPT) can help doctors start and monitor allergy immunotherapy more effectively. Researchers will follow 200 adults with allergic rhinitis who are beginning immunotherapy, using the NAPT along with blood tests and symptom questionnaires over three years. The goal is to see if this approach can improve treatment outcomes and reduce costs by tailoring therapy to each person's specific allergies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Allergen immunotherapy (AIT) – allergy shots or drops
What this could lead to: If successful, this could help doctors personalize allergy treatment, saving time and money by only treating the allergens that matter most.
What could go wrong: This is an observational study, not a test of a new treatment. It may not lead to changes in practice, and results depend on patient participation over three years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCAL ALLERGIC RHINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic rhinitis perennial allergic rhinitis seasonal allergic rhinitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCAL ALLERGIC RHINITIS PERENNIAL ALLERGIC RHINITIS SEASONAL ALLERGIC RHINITIS

Contacts and locations

Locations

AZ Sint-Jan
NOT_YET_RECRUITING

Bruges, 8000, Belgium
UZ Leuven
RECRUITING

Leuven, Vlaam Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.